Association of HER2 protein expression with clinicopathologic features and prognosis in Chinese patients with gastric carcinoma

Chinese Journal of Pathology

Volumn 40, Issue 5, 2011, Pages 296-299

  Wu, Hong Mei ^a   Liu, Yan Hui ^a   Lin, Feng ^a   Xu, Fang Ping ^a   Luo, Dong Lan ^a   Zhang, Fen ^a   Zhuang, Heng Guo ^a   Luo, Xin Lan ^a   Wu, Wu Lin ^a   Lin, Xing Tao ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Genes, erbb 2; Immunohistochemistry; Prognosis; Stomach neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASIAN; CANCER STAGING; COLLOID CARCINOMA; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SIGNET RING CARCINOMA; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SIGNET RING CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 79961096442     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2011.05.003     Document Type: Article

References (15)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 2006, 24 (14): 2137-2150. (Pubitemid 46655601)
2. Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 1986, 232(4758) : 1644-1646. (Pubitemid 16095607)
3. Koeppen HK, Wright BD, Burt AD, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology, 2001, 38(2): 96-104. (Pubitemid 32194449)
4. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer, 2002, 98 (6): 833-837. (Pubitemid 34286677)
5. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.J Natl Cancer Inst, 1986, 77(5): 1047-1052.
6. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol, 2007, 59(6): 795-805. (Pubitemid 46440603)
7. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res, 1991, 51 (3): 1034-1038.
8. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer, 1993, 72(11): 3179-3184.
9. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52(7): 797-805. (Pubitemid 351724903)
10. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer ( ToGA ): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.
11. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch, 2010, 457(3): 299-307.
12. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer, 2009, 100 (3): 487-493.
13. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value conclusions from 924 cases of two independent series. Cell Oncol, 2010, 32(1-2): 57-65.
14. García I, Vizoso F, Martín A, et al. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol, 2003, 10(3): 234-241. (Pubitemid 40486955)
15. Carneiro F, Sobrinho-Simoes M. The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer, 2000, 88(1): 238-240.